Lymphoma after living donor kidney transplantation: An Iranian multicenter experience

International Urology and Nephrology

Volumn 40, Issue 4, 2008, Pages 1089-1094

  Pourfarziani, Vahid ^a,b   Taheri, Saeed ^a   Lessan Pezeshki, Mahboob ^a   Nourbala, Mohammad Hossein ^a,b   Simforoosh, Naser ^c   Nemati, Eghlim ^a,b   Makhdoomi, Khadijeh ^a,d   Ghafari, Ali ^a,d   Ahmadpour, Pedram ^a,d   Nafar, Mohsen ^c   Einollahi, Behzad ^a,b  

^a Baqiyatallah Medical Sciences University Baqyatallah Hospital   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Incidence; Iran; Living renal transplantation; Lymphoproliferative disorders; PTLD

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRANIAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; IRAN; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 56249094144     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9377-0     Document Type: Article

References (21)

1. Penn I, Hammond W, Brettschneider L et al (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1(1):106-112
2. Niaudet P (1998) Postransplant lymphoproliferative disease following renal transplantation: A multicenter retrospective study of 41 cases observed between 1992 and 1996. French speaking transplantation workshop. Transplant Proc 30(6):2816-2817
3. Trofe J, Buell JF, Beebe TM et al (2005) Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn international transplant tumor registry experience. Am J Transplant 5(4 Pt 1):775-780
4. Loren AW, Tsai DE (2005) Post-transplant lymphoproliferative disorder. Clin Chest Med 26(4):631-645 vii. Review
5. Opelz G (1996) Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 11(10):1952-1955
6. Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3(2):70-78
7. Dharnidharka VR, Tejani AH, Ho PL (2002) Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2(10):993-998
8. Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:222-230
9. Penn I (1998) De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 2(1):56-63
10. Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342(8886-8887):1514-1516
11. Shahinian VB, Muirhead N, Jevnikar AM et al (2003) Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 75(6):851-856
12. Gandhi MK (2006) Epstein-Barr virus-associated lymphomas. Expert Rev Anti Infect Ther 4(1):77-89
13. Gandhi MK, Khanna R (2005) Viruses and lymphoma. Pathology 37(6):420-433
14. Preiksaitis JK (2004) New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 39(7):1016-1023
15. Caillard S, Lelong C, Pessione F et al (2006) Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French registry. Am J Transplant 6(11):2735-2742
16. Bustami RT, Ojo AO, Wolfe RA et al (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4(1):87-93
17. Jain M, Badwal S, Pey R (2005) Post-transplant lymphoproliferative disorders after live donor renal transplantation. Clin Transplant 19(5):668-73
18. Bates WD, Gray DW, Dada MA (2003) Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 56(6):439-446
19. Cosio FG, Nuovo M, Delgado L et al (2004) EBV kidney allograft infection: Possible relationship with a peri-graft localization of PTLD. Am J Transplant 4(1):116-123
20. Einollahi B, Pourfarziani V, Ahmadzad-Asl M et al (2007) Iranian model of renal allograft transplantation in 3028 recipients: Survival and risk factors. Transplant Proc 39(4):907-10
21. Wimmer CD, Rentsch M, Crispin A (2007) The Janus face of immunosuppression-de novo malignancy after renal transplantation: The experience of the Transplantation Center Munich. Kidney Int 71(12):1271-8